Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aptar’s Nasal Unidose System to Deliver neffy® for Needle-Free Anaphylaxis Treatment
Details : Neffy (epinephrine) is a nasal spray that acts as a adrenergic receptor agonist. It is approved by FDA for the treatment of Type I allergies, including anaphylaxis.
Brand Name : Neffy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 15, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Metronidazole
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aptar Pharma’s Airless+ system Delivers China NMPA Approved Rosacea Treatment
Details : NMPA approved an bacterial DNA synthesis inhibitor antibiotic, metronidazole gel for papulopustular rosacea, which uses Aptar Pharma’s Mezzo+ CS Airless dispensing solution for dermal drug delivery.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 11, 2024
Lead Product(s) : Metronidazole
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : TFF Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The development of an effective intranasal vaccine has numerous potential advantages over conventional, subcutaneous or intramuscular-based delivery.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
November 03, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : TFF Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Recipient : Pharmaxis
Deal Size : Undisclosed
Deal Type : Acquisition
Aptar Pharma Acquires Worldwide License for Orbital™ High Payload Dry Powder Inhaler
Details : Pharmaxis’ proprietary Orbital™ inhaler, a unique device designed to deliver high payload dry powder to the lungs.This unique platform was originally developed as a life cycle extending product for the Pharmaxis cystic fibrosis drug Bronchitol® (man...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 04, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Recipient : Pharmaxis
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Indivior
Deal Size : $2.1 million
Deal Type : Collaboration
Details : The agreement includes an investment by Opiant and a commitment by Aptar to install and maintain equipment in support of increased future production of its Unidose device to meet the potential commercial demand for OPNT003, nasal nalmefene.
Brand Name : OPNT003
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 08, 2022
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Indivior
Deal Size : $2.1 million
Deal Type : Collaboration
Lead Product(s) : Mannitol API
Therapeutic Area : Genetic Disease
Study Phase : Approved
Recipient : Pharmaxis
Deal Size : Undisclosed
Deal Type : Agreement
Details : As per agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device & further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to de...
Brand Name : Bronchitol
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 17, 2021
Lead Product(s) : Mannitol API
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Recipient : Pharmaxis
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Indivior
Deal Size : Undisclosed
Deal Type : Partnership
Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment
Details : Agreement combines Opiant’s opioid antagonist OPNT003 nasal nalmefene, with Aptar's FDA-approved Unit Dose System delivery device. OPNT003 is a nasal nalmefene for use in conjunction with Aptar’s Unit Dose System (UDS) for the treatment of opioid ove...
Brand Name : OPNT003
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 29, 2020
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Indivior
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?